Clovis Oncology, Inc. (CLVS)
CLVSPrice: $0.08
Fair Value: 🔒
🔒score
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recu... more
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercial... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Patrick Mahaffy |
| IPO Date | 2011-11-16 | CAGR | — |
| Employees | 413 | Website | www.clovisoncology.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CLVS chart loading...
Fundamentals
Technicals
| Enterprise Value | $572.35M | P/E Ratio | -0.04 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | -0.04 |
| P/CF Ratio | -0.05 | P/FCF Ratio | — |
| EPS | $-2.08 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -33.56% | Gross Margin | 0.74% |
| Operating Margin | -1.57% | Profit Margin | -1.78% |
| ROE | 1.21% | ROA | -0.56% |
| ROCE | -0.67% | Current Ratio | 1.58 |
| Quick Ratio | 1.47 | Cash Ratio | 1.15 |
| Debt/Equity | -2.29 | Interest Coverage | -7.36 |
| Altman Z Score | — | Piotroski Score | — |